Kappa Light Chains free

Cancer

Report in 24Hrs

At Home

No Fasting Required

Details

Measures immunoglobulin light chains.

₹3,404₹4,863

30% OFF

Kappa Light Chains Free - Comprehensive Medical Test Guide

Why is it done?
- Measures free kappa light chains produced by plasma cells in the blood to assess monoclonal protein disorders
- Screen for multiple myeloma, light chain disease, and other plasma cell dyscrasias
- Monitor progression and treatment response in patients with known monoclonal gammopathy
- Evaluate kidney disease associated with light chain deposition or cast nephropathy
- Assess patients with suspected amyloidosis (AL amyloidosis)
- Calculate kappa/lambda ratio to differentiate monoclonal from polyclonal proteinemia
- Typically ordered when abnormal serum protein electrophoresis is detected or monoclonal disease is suspected
Normal Range
- Reference Range: 0.33 - 1.94 mg/dL (3.3 - 19.4 mg/L)
- Unit of Measurement: mg/dL or mg/L (milligrams per deciliter or per liter)
- Normal Result: Free kappa light chains within reference range indicates normal B-cell function and no monoclonal protein production
- Elevated Result: Kappa light chains above 1.94 mg/dL may indicate monoclonal gammopathy, multiple myeloma, or light chain disease
- Kappa/Lambda Ratio: Normal range is 0.26 - 1.65; ratio >1.65 suggests kappa predominance (monoclonal); ratio <0.26 suggests lambda predominance
- Note: Reference ranges may vary slightly between laboratories; always consult the specific lab's reference range
Interpretation
- Mildly Elevated (1.95 - 3.0 mg/dL): May indicate early monoclonal gammopathy or MGUS (monoclonal gammopathy of undetermined significance); warrants follow-up testing and monitoring
- Moderately Elevated (3.1 - 10.0 mg/dL): Consistent with light chain myeloma, primary light chain disease, or active monoclonal gammopathy; typically requires additional workup
- Markedly Elevated (>10.0 mg/dL): Strongly suggestive of multiple myeloma, light chain disease, or AL amyloidosis; requires immediate clinical evaluation and further testing
- Abnormal Kappa/Lambda Ratio: Markedly abnormal ratios (<0.13 or >1.65) are highly suggestive of monoclonal light chain disease; normal ratio argues against monoclonal disease
- Factors Affecting Results: Renal function (impaired kidney function elevates free light chains), dehydration, infection, inflammation, recent chemotherapy, and age-related changes in immune function
- Serial Monitoring: Trending changes are more clinically significant than single measurements; increasing kappa levels suggest disease progression; decreasing levels suggest treatment response
- Clinical Context: Results must be interpreted with clinical presentation, patient symptoms, renal function, and other laboratory findings; elevated free light chains with normal kidney function is more specific for monoclonal disease
Associated Organs
- Primary Organ Systems: Hematologic system (bone marrow and plasma cells), immune system, and kidneys
- Multiple Myeloma: Malignant transformation of plasma cells in bone marrow; elevated kappa light chains are hallmark of this disease
- Light Chain Disease: Proliferation of plasma cells producing free light chains that may accumulate in kidneys causing myeloma kidney or cast nephropathy
- AL Amyloidosis: Misfolded light chains form amyloid fibrils depositing in heart, kidneys, nerves, and other organs causing organ dysfunction
- Kidney Disease: Elevated free light chains can cause acute or chronic kidney injury through tubular obstruction (myeloma kidney), glomerular deposition, or amyloid accumulation; can lead to dialysis dependence
- MGUS (Monoclonal Gammopathy of Undetermined Significance): Benign condition with low-level monoclonal protein; carries risk of progression to myeloma or AL amyloidosis requiring monitoring
- Light Chain Deposition Disease (LCDD): Abnormal light chain deposition in kidney causing glomerulonephritis and progressive renal failure
- Waldenström Macroglobulinemia: Lymphoid malignancy producing monoclonal IgM protein with associated light chains
Follow-up Tests
- Lambda Light Chains: Simultaneously ordered to calculate kappa/lambda ratio and fully characterize light chain profile
- Serum Protein Electrophoresis (SPEP): Detects and characterizes monoclonal proteins; often ordered concurrently with free light chains
- Immunofixation Electrophoresis (IFE): Confirms monoclonal protein type and light chain type (kappa or lambda) with high specificity
- 24-Hour Urine Protein Electrophoresis: Detects light chains in urine (Bence Jones proteins); important for diagnosing light chain disease and myeloma kidney
- Complete Blood Count (CBC): Assesses for anemia, thrombocytopenia, and other cytopenias associated with bone marrow involvement
- Comprehensive Metabolic Panel (CMP): Evaluates kidney function (creatinine, BUN), serum calcium, and electrolytes affected by myeloma
- Bone Marrow Biopsy: Performed when multiple myeloma is suspected; determines plasma cell percentage and cytogenetics
- Skeletal Survey or PET-CT: Imaging to detect bone lesions and lytic disease in suspected myeloma cases
- Flow Cytometry: Bone marrow or peripheral blood flow cytometry confirms monoclonal plasma cells and characterizes abnormal B-cell population
- Cardiac and Organ Assessment: Echocardiography, EMG, kidney biopsy may be needed for suspected AL amyloidosis to detect organ involvement
- Monitoring Schedule for Confirmed Disease: Every 4-8 weeks during treatment, every 3-6 months after treatment completion, or as clinically indicated based on disease status
- MGUS Follow-up: Repeat testing every 6-12 months to detect progression; higher risk patients may need more frequent monitoring
Fasting Required?
- Fasting Required: No
- Food and Drink: You may eat and drink normally before this test; no dietary restrictions required
- Medications: Take all regular medications as prescribed; no medications need to be withheld before blood draw
- Hydration: Good hydration is beneficial as dehydration can affect light chain measurements; drink water normally
- Sample Collection: Serum sample obtained by venipuncture (blood draw); can be performed at any time of day
- Timing Considerations: If monitoring disease progression, try to draw blood at consistent times (e.g., morning) for better trend comparison
- Patient Preparation: Inform phlebotomist of any recent chemotherapy, immunosuppressive therapy, or acute illness that may affect immune function and results
- No Special Instructions: Unlike some other blood tests, no special preparation is needed beyond standard phlebotomy precautions

How our test process works!